MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MK-5108

CAS No. : 1010085-13-8

MCE 站：MK-5108

产品活性：MK-5108是高效和特异性的极光激酶A抑制剂，IC₅₀ 值为0.064 nM。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics  |  Autophagy

作用靶点：Aurora Kinase  |  Autophagy

In Vitro: MK-5108 inhibits Aurora-A activity with an IC₅₀ value of 0.064 nM in an ATP-competitive manner. It shows robust selectivity against the other family kinases Aurora-B (220-fold) and Aurora-C (190-fold). MK-5108 also exhibits high selectivity for Aurora-A over other protein kinases. MK-5108 inhibits the growth of 14 cell lines with IC₅₀ values between 0.16 and 6.4 μM.

In Vivo: MK-5108 treatments at 15 and 30 mg/kg results in significant tumor growth inhibition in the HCT116 tumor model. MK-5108 is well tolerated at both doses, with minimal reduction in body weight. MK-5108 also exhibits significant antitumor activity in nude rats bearing SW48 tumors. MK-5108 at 15 and 45 mg/kg causes dose-dependent tumor growth inhibition with a %T/C of 35% and 7% at day 10, and 58% and 32% at day 27, respectively. MK-5108 is well tolerated in nude rats, with no body weight reduction and moderate effect on blood cells.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Kinase Inhibitor Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Cytoskeleton Compound Library  |  Anti-Blood Cancer Compound Library  |  AT9283  |  KW-2449  |  PF-03814735  |  ZM-447439  |  SNS-314 mesylate  |  CCT 137690  |  SCH-1473759 hydrochloride  |  NU6140  |  Aurora kinase inhibitor-2  |  Tripolin A  |  Aurora B inhibitor 1  |  Aurora inhibitor 1

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。